{"product_id":"stanos-stanozolol","title":"Stanos (Stanozolol)","description":"\u003ch4\u003e\u003cspan class=\"\"\u003eAbout the Product\u003c\/span\u003e\u003c\/h4\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eStanos\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e is a research compound from Driada Medical, containing \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eStanozolol\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e. Stanozolol is a synthetic anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of dihydrotestosterone (DHT)\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/evsexplore.semantics.cancer.gov\/evsexplore\/concept\/ncim\/C0038149\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. Its chemical formula is C₂₁H₃₂N₂O, with a molecular weight of 328.5 g\/mol and a CAS number of 10418-03-8\u003c\/span\u003e\u003ca href=\"https:\/\/www.cerilliant.com\/products\/COA\/NMID646.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan class=\"\"\u003eThe compound is characterized by a unique structural feature—a \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003epyrazole ring fused to the A-ring\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e of the steroid nucleus\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. This modification, combined with its 5α-reduced structure and 17α-methyl group\u003c\/span\u003e\u003ca href=\"https:\/\/evsexplore.semantics.cancer.gov\/evsexplore\/concept\/ncim\/C0038149\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e, provides two key characteristics for research purposes:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan class=\"\"\u003eThe \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003e17α-methyl group\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e hinders hepatic metabolism, enabling bioavailability for oral research models\u003c\/span\u003e\u003ca href=\"https:\/\/evsexplore.semantics.cancer.gov\/evsexplore\/concept\/ncim\/C0038149\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan class=\"\"\u003eThe \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003e5α-reduced structure\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e prevents aromatization to estrogen, differentiating its receptor activity from testosterone\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan class=\"\"\u003eThe product is intended for \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003elaboratory research use only\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e and features an integrated QR code on the packaging for detailed product verification.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eProduct Name:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Stanos (Stanozolol)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eBrand:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Driada Medical\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eForm:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Solution for research applications\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eCAS:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e 10418-03-8\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eFor Research Use Only.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch4\u003e\u003cspan class=\"\"\u003eResearch Applications \u0026amp; Mechanism of Action\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eParadoxical Androgen Receptor Agonist:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Stanozolol functions as an agonist at the androgen receptor (AR)\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/evsexplore.semantics.cancer.gov\/evsexplore\/concept\/ncim\/C0038149\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. However, its mechanism presents a distinct research profile: despite having a \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003elow binding affinity\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e for the AR (approximately 22% of DHT in some studies, or a relative binding affinity of \u0026lt;0.05 compared to methyltrienolone)\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/scholars.houstonmethodist.org\/en\/publications\/relative-binding-affinity-of-anabolic-androgenic-steroids-compari\/\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e, stanozolol is a \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003epotent activator\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e of AR-mediated transcription and signaling\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0960076005000622\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan class=\"\"\u003eThis paradox—low affinity but strong transcriptional activation—is a key area of research interest. Studies suggest that stanozolol may induce a distinct conformational change in the AR upon binding, which effectively promotes the recruitment of transcriptional coactivators and the displacement of corepressors\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eAnabolic Profile:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Relative to testosterone (ratio 1:1), the anabolic:androgenic ratio of stanozolol in rodent models is approximately \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003e1:1 to 1:3\u003c\/span\u003e\u003c\/strong\u003e\u003ca href=\"https:\/\/en.wikipedia.org\/api\/rest_v1\/page\/mobile-html\/Template:Relative_androgenic_to_anabolic_activity_in_animals\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. It is classified as having weak AR binding, yet in transactivation assays, it functions as a potent activator\u003c\/span\u003e\u003ca href=\"https:\/\/scholars.houstonmethodist.org\/en\/publications\/relative-binding-affinity-of-anabolic-androgenic-steroids-compari\/\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0960076005000622\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eSerum Protein Binding:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Stanozolol exhibits very low affinity for serum sex hormone-binding globulin (SHBG), resulting in a significantly higher fraction of the compound circulating in the free, unbound state (the pharmacologically active form), which influences its bioavailability\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/scholars.houstonmethodist.org\/en\/publications\/relative-binding-affinity-of-anabolic-androgenic-steroids-compari\/\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eGene Expression Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e The compound has been shown to regulate the expression of various genes, including the androgen receptor (AR) itself, Fas Receptor (FasR), and 5-alpha reductase 2 (SRD5A2) in certain cell models\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eCardiovascular \u0026amp; Metabolic Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Animal studies have demonstrated that stanozolol administration can lead to \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003ecardiac hypertrophy\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e, increased mean arterial pressure, and alterations in baroreflex control of heart rate\u003c\/span\u003e\u003ca href=\"https:\/\/link-proxy.springer.com\/article\/10.1186\/s40360-026-01086-3\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0960076004004078\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. It can also induce oxidative stress and activate inflammatory signaling pathways (e.g., NF-κB\/P65) in cardiac tissue\u003c\/span\u003e\u003ca href=\"https:\/\/link-proxy.springer.com\/article\/10.1186\/s40360-026-01086-3\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eHepatotoxicity Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Human case studies reveal a specific biochemical profile of stanozolol-induced liver injury characterized by marked elevation of bilirubin, mild rise in transaminases, and near-normal GGT\u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0973688325000064\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.semanticscholar.org\/paper\/Stanozolol-induced-Liver-Injury:-A-Distinctive-and-Nunes-Schinoni\/be32444953f4730e88d05b662a4f2abafab8ae87\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch4\u003e\u003cspan class=\"\"\u003eResearch \u0026amp; Scientific Background\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eChemical Background:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Stanozolol is a 17α-alkylated anabolic steroid formed by the condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine\u003c\/span\u003e\u003ca href=\"https:\/\/evsexplore.semantics.cancer.gov\/evsexplore\/concept\/ncim\/C0038149\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. It was historically used to treat various medical conditions, including anemia and hereditary angioedema\u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0973688325000064\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eAndrogen Receptor Binding \u0026amp; Activation Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Several studies have characterized stanozolol's distinct pharmacology:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan class=\"\"\u003eA 1984 study found its relative binding affinity to the AR was \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eless than 0.05\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e compared to methyltrienolone, a reference compound\u003c\/span\u003e\u003ca href=\"https:\/\/scholars.houstonmethodist.org\/en\/publications\/relative-binding-affinity-of-anabolic-androgenic-steroids-compari\/\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan class=\"\"\u003eSubsequent research (2005) confirmed that while stanozolol is a low-affinity ligand for the AR in vitro, it is a potent activator in cell-based transactivation assays\u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0960076005000622\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan class=\"\"\u003eComputational docking studies distinguish its binding energy profile from other oral steroids such as methyltestosterone and oxandrolone\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eIn Vivo Studies:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e In rat models, stanozolol administered at doses of 5 mg\/kg\/week caused increases in mean arterial pressure (control: 116 ± 2 mmHg; treated: 126 ± 2.5 mmHg), cardiac output, and cardiac hypertrophy\u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0960076004004078\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. Higher doses (20 mg\/kg\/week) resulted in increased total peripheral resistance\u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0960076004004078\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eHuman Liver Injury Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e A prospective study (2025) evaluating 18 cases of stanozolol-induced liver injury found a \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003emean latency to symptom onset of 55 days\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e. The cohort consisted of young males (ages 19–48) using stanozolol for aesthetic purposes. Doses reported ranged from \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003e50 to 200 mg daily or three times weekly\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e for up to 8 weeks\u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0973688325000064\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.semanticscholar.org\/paper\/Stanozolol-induced-Liver-Injury:-A-Distinctive-and-Nunes-Schinoni\/be32444953f4730e88d05b662a4f2abafab8ae87\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eGenetic Variability Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e While direct studies on stanozolol pharmacogenomics are limited, the field of pharmacogenomics indicates that genetic variations in drug-metabolizing enzymes can influence compound response. Stanozolol's distinct AR activation profile and receptor binding dynamics provide a basis for investigating how genetic factors may influence individual responses in research models\u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/product\/B1681124\/docs\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Driada","offers":[{"title":"Default Title","offer_id":58726426214725,"sku":null,"price":35.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1077\/7614\/7781\/files\/Driada-Stanos.jpg?v=1785449582","url":"https:\/\/genetic-peps.shop\/products\/stanos-stanozolol","provider":"Genetic Peps","version":"1.0","type":"link"}